

DAFTAR PUSTAKA

Abbexa (2023) Instructions for Use: Human Gremlin 1 (GREM1) ELISA Kit, Abbexa BV.

Abdesselam, A. et al. (2021) 'Estimate of the homa-ir cut-off value for identifying subjects at risk of insulin resistance using a machine learning approach', *Sultan Qaboos University Medical Journal*, 21(4), pp. 604–612. Available at: <https://doi.org/10.18295/squmj.4.2021.030>.

Ahmed, B., Sultana, R. and Greene, M.W. (2021) 'Adipose tissue and insulin resistance in obese', *Biomedicine & Pharmacotherapy*, 137, p. 111315. Available at: <https://doi.org/10.1016/j.biopha.2021.111315>.

Al-Regaiey, K.A. et al. (2022) 'Relationship of Plasma Gremlin 1 Levels with Body Adiposity and Glycemic Control in Saudi Female Type 2 Diabetes Patients', *Diabetes, Metabolic Syndrome and Obesity*, 15, pp. 3429–3436. Available at: <https://doi.org/10.2147/DMSO.S372146>.

Ayoub S, Farnaz S, Soltani M, Daraei A, Shirvani H, Laher I, et al. Resistance training, gremlin 1 and macrophage migration inhibitory factor in obese men: a randomised trial. *Archives of Physiology and Biochemistry*. 2020 Dec 28;1–9.

Ayuningtyas D, Kusuma D, Amir V, Tjandrarini DH, Andarwati P. Disparities in Obesity Rates among Adults: Analysis of 514 Districts in Indonesia. *Nutrients*. 2022 Aug 14;14(16):3332.

Babak Arjmand, Saeed Ebrahimi Fana, Ghasemi E, Ameneh Sadat Kazemi, Robabeh Ghodssi-Ghassemabadi, Hojat Dehghanbanadaki, et al. Metabolic signatures of insulin resistance in non-diabetic individuals. *BMC Endocrine Disorders*. 2022 Aug 24;22(1).

Choi, S.W. et al. (2023) 'Adipokine gremlin-1 promotes hepatic steatosis via upregulation of ER stress by suppressing autophagy-mediated signaling', *Journal of Cellular Physiology* [Preprint]. Available at: <https://doi.org/10.1002/jcp.30982>.

Deng, K. et al. (2022) 'Temporal relationship among adiposity, gut microbiota, and insulin resistance in a longitudinal human cohort', *BMC Medicine*, 20(1). Available at: <https://doi.org/10.1186/s12916-022-02376-3>.

Deischinger C, Bastian M, Leitner K, Bancher-Todesca D, Kiss H, Baumgartner-Parzer S, et al. Gremlin-1 in pregnancy and postpartum: relation to the fatty liver index, markers of bone health, glucose metabolism and gestational diabetes mellitus status. *Acta Diabetologica*. 2023 Jul 30;60(12):1699–707.

Elabscience (2022) 'Copyright ©2020-2021 Elabscience Biotechnology Inc. All Rights Reserved' *Human A-GHRL(Acylated Ghrelin) ELISA Kit United States*, 1st Editio, p.



al. (2022) 'Insights into the Role of Gremlin-1, a Bone Morphogenic Protein in Cancer Initiation and Progression', *Biomedicines*, 10(2), p. 301. Available at: doi.org/10.3390/biomedicines10020301.

- Gastaldelli, A. (2022) 'Measuring and estimating insulin resistance in clinical and research settings', *Obesity*, 30(8), pp. 1549–1563. Available at: <https://doi.org/10.1002/oby.23503>.
- Grillo, E. et al. (2023) 'Role of gremlin-1 in the pathophysiology of the adipose tissues', *Cytokine & Growth Factor Reviews*, 69, pp. 51–60. Available at: <https://doi.org/10.1016/j.cytogfr.2022.09.004>.
- Grillo E, Ravelli C, Colleluori G, D'Agostino F, Mattia Domenichini, Giordano A, et al. Role of gremlin-1 in the pathophysiology of the adipose tissues. *Cytokine & Growth Factor Reviews*. 2023 Feb 1;69:51–60.
- Harbuwono, D.S. et al. (2018) 'Obesity and central obesity in Indonesia: evidence from a national health survey', *Medical Journal of Indonesia*, 27(2), pp. 114–20. Available at: <https://doi.org/10.13181/mji.v27i2.1512>.
- Hedjazifar, S. et al. (2020) 'The novel adipokine gremlin 1 antagonizes insulin action and is increased in type 2 diabetes and NAFLD/NASH', *Diabetes*, 69(3), pp. 331–341. Available at: <https://doi.org/10.2337/db19-0701>.
- HORIBA (2017) 'ABX Pentra 400 Clinical Chemistry System', at: www.horiba.com/us/en/medical.
- Jenkins, H.N. et al. (2020) 'Endothelin-1 in the pathophysiology of obesity and insulin resistance', *Obesity Reviews*, 21(12). Available at: <https://doi.org/10.1111/obr.13086>.
- Kojta, I., Chacińska, M. and Błachnio-Zabielska, A. (2020) 'Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance', *Nutrients*, 12(5), p. 1305. Available at: <https://doi.org/10.3390/nu12051305>.
- Kern L, Mittenbühler M, Vesting A, Ostermann A, Wunderlich C, Wunderlich F. Obesity-Induced tnfa and IL-6 Signaling: The Missing Link between Obesity and Inflammation—Driven Liver and Colorectal Cancers. *Cancers* [Internet]. 2019 Dec 27;11(1):24. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356226/>
- Khalid Al-Regaiey, Syed Shahid Habib, Alshamasi AR, Alnuwaybit AF, Alwhaibi BA, Alsulais NM, et al. Relationship of Plasma Gremlin 1 Levels with Body Adiposity and Glycemic Control in Saudi Female Type 2 Diabetes Patients. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* [Internet]. 2022 Nov 1 [cited 2023 Nov 15];Volume 15:3429–36. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639591/>
- Kim KB, Shin YA. Males with Obesity and Overweight. *Journal of Obesity & Metabolic Syndrome*. 2020 Mar 30;29(1):18–25.

Kojta, I., Chacińska, M. and Błachnio-Zabielska, A. (2020) 'Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance', *Nutrients*, 12(5), p. 1305. Available at: <https://doi.org/10.3390/nu12051305>.



(2019) 'Gremlin-1 and gremlin-2 levels in polycystic ovary syndrome and their relations', *Gynecological Endocrinology*, 35(7), pp. 604–607. Available at: <https://doi.org/10.1080/09513590.2019.1566452>.

Kruszewska, J., Laudy-Wiaderny, H. and Kunicki, M. (2022) 'Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients—The Debate Is Still Open', International Journal of Environmental Research and Public Health. MDPI. Available at: <https://doi.org/10.3390/ijerph19042099>.

Kurniawan, L. et al. (2018) 'Body Mass, Total Body Fat Percentage, and Visceral Fat Level Predict Insulin Resistance Better Than Waist Circumference and Body Mass Index in Healthy Young Male Adults in Indonesia', Journal of Clinical Medicine, 7(5), p. 96. Available at: <https://doi.org/10.3390/jcm7050096>.

Kurniawan, L.B. et al. (2020) 'Anthropometric features in predicting insulin resistance among non-menopausal Indonesian adult females', Romanian Journal of Internal Medicine, 58(3), pp. 168–172. Available at: <https://doi.org/10.2478/rjim-2020-0015>.

Lee, S.-H., Park, S.-Y. and Choi, C.S. (2022) 'Insulin Resistance: From Mechanisms to Therapeutic Strategies', Diabetes & Metabolism Journal, 46(1), pp. 15–37. Available at: <https://doi.org/10.4093/dmj.2021.0280>.

Mastrototaro, L. and Roden, M. (2021) 'Insulin resistance and insulin sensitizing agents', Metabolism, 125, p. 154892. Available at: <https://doi.org/10.1016/j.metabol.2021.154892>.

Montserrat-Mesquida M, Quetglas-Llabrés M, Capó X, Bouzas C, Mateos D, Pons A, et al. Metabolic Syndrome Is Associated with Oxidative Stress and Proinflammatory State. Antioxidants. 2020 Mar 12;9(3):236.

Oddo VM, Maehara M, Rah JH. Overweight in Indonesia: an observational study of trends and risk factors among adults and children. BMJ Open. 2019 Sep;9(9):e031198

O'Reilly, S. (2021) 'Circulating Gremlin-1 is elevated in systemic sclerosis patients', Journal of Scleroderma and Related Disorders, 6(3), pp. 286–289. Available at: <https://doi.org/10.1177/23971983211036571>.

Ormazabal, V. et al. (2018) 'Association between insulin resistance and the development of cardiovascular disease', Cardiovascular Diabetology. Cardiovasc Diabetol. Available at: <https://doi.org/10.1186/s12933-018-0762-4>.

Park, S.Y., Gautier, J.-F. and Chon, S. (2021) 'Assessment of Insulin Secretion and Insulin Resistance in Human', Diabetes & Metabolism Journal, 45(5), pp. 641–654. Available at: <https://doi.org/10.4093/dmj.2021.0220>.

Roche (2013) *Insulin*. Indianapolis: Roche Diagnostic.

Rodríguez, A. et al. (2020) 'Adipose tissue depot differences in adipokines and effects on skeletal and cardiac muscle', Current Opinion in Pharmacology, 52, pp. 1–8. Available at: <https://doi.org/10.1016/j.coph.2020.04.003>.



al. (2023) 'The threshold value for identifying insulin resistance (HOMA-IR) in adolescent population: A hyperglycemic clamp validated study', Archives of Physiology and Metabolism, 67(1), pp. 119–125. Available at: <https://doi.org/10.20945/2359-3997000000533>.

- Sugiyono (2011) Metode Penelitian Kuantitatif, Kualitatif dan R&D. Bandung: Alfabeta. Vladu, I. et al. (2021) 'Insulin resistance quantified by the value of HOMA IR and cardiovascular risk in patients with type 2 diabetes', *Experimental and Therapeutic Medicine*, 23(1). Available at: <https://doi.org/10.3892/etm.2021.10996>.
- Wadley A, Roberts M, Creighton J, Thackray A, Stensel D, Bishop N. Higher levels of physical activity are associated with reduced tethering and migration of pro-inflammatory monocytes in males with central obesity. *Repositorylboroacuk* [Internet]. 2021 Apr 1 [cited 2023 Nov 14]; Available from: https://repository.lboro.ac.uk/articles/journal_contribution/Higher_levels_of_physical_activity_are_associated_with_reduced_tethering_and_migration_of_pro-inflammatory_monocytes_in_males_with_central_obesity/14717157
- Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2020 Oct;Volume 13:3611–6.
- World Health Organization. Obesity and overweight [Internet]. World Health Organization. 2021. Available from: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>
- Yang S, Zhang Y, Hua Y, Cui M, Wang M, Gao J, et al. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. *Frontiers in Oncology* [Internet]. 2022 Aug 26 [cited 2023 Nov15];12:968610. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458890/>
- Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and Cancer. *Diabetes & Metabolism Journal*. 2021 Mar 29;



Lampiran 1. Analisa SPSS

Uji Normalitas

IMT

Case Processing Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
IMT	76	100.0%	0	0.0%	76	100.0%

Descriptives

		Statistic	Std. Error
IMT	Mean	26.874	.5983
	95% Confidence Interval for Mean	Lower Bound	25.682
		Upper Bound	28.065
	5% Trimmed Mean	26.821	
	Median	27.600	
	Variance	27.201	
	Std. Deviation	5.2155	
	Minimum	18.2	
	Maximum	39.4	
	Range	21.2	
	Interquartile Range	8.9	
	Skewness	.006	.276
	Kurtosis	-.964	.545




Tests of Normality

Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	df	Sig.	Statistic	df	Sig.
	76	.200 [*]	.962	76	.023

and of the true significance.

a. Lilliefors Significance Correction






IMT Stem-and-Leaf Plot

Frequency	Stem &	Leaf
8,00	1 .	88888999
21,00	2 .	000000111112222333344
23,00	2 .	55567777778888888999999
21,00	3 .	000001111122233333344
3,00	3 .	559

Stem width: 10,0
Each leaf: 1 case(s)







Kadar GDP

Case Processing Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
Kadar GDP	76	100.0%	0	0.0%	76	100.0%

Descriptives


			Statistic	Std. Error
Kadar GDP	Mean		95.67	.994
	95% Confidence Interval for Mean	Lower Bound	93.69	
		Upper Bound	97.65	
	5% Trimmed Mean		95.76	
	Median		95.00	
	Variance		75.157	
	Std. Deviation		8.669	
	Minimum		75	
	Maximum		114	
	Range		39	
	Interquartile Range		12	
	Skewness		.015	.276
	Kurtosis		.004	.545

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Kadar GDP	.095	76	.089	.979	76	.235

a. Lilliefors Significance Correction








Kadar GDP Stem-and-Leaf Plot

Frequency	Stem &	Leaf
,00	7 .	
4,00	7 .	5588
,00	8 .	
14,00	8 .	55667777889999
19,00	9 .	012222222233333334
16,00	9 .	55556666778888899
9,00	10 .	000223334
9,00	10 .	555667888
5,00	11 .	02344

Stem width: 10
Each leaf: 1 case(s)







Kadar Insulin

Case Processing Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
Kadar Insulin	76	100.0%	0	0.0%	76	100.0%

Descriptives


			Statistic	Std. Error
Kadar Insulin	Mean		11.7334	.61903
	95% Confidence Interval for Mean	Lower Bound	10.5002	
		Upper Bound	12.9666	
	5% Trimmed Mean		11.5301	
	Median		11.0350	
	Variance		29.123	
	Std. Deviation		5.39660	
	Minimum		2.74	
	Maximum		23.47	
	Range		20.73	
	Interquartile Range		8.35	
	Skewness		.512	.276
	Kurtosis		-.672	.545

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Kadar Insulin	.095	76	.084	.950	76	.005

a. Lilliefors Significance Correction








Kadar Insulin Stem-and-Leaf Plot

Frequency	Stem & Leaf
5,00	0 . 24444
29,00	0 . 55555555666667777788888899999
22,00	1 . 0001111112233333334444
14,00	1 . 55567777888999
6,00	2 . 112333

Stem width: 10,00
Each leaf: 1 case(s)







Kadar HOMA.IR

Case Processing Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
kadar HOMA.IR	76	100.0%	0	0.0%	76	100.0%

Descriptives

		Statistic	Std. Error
kadar HOMA.IR	Mean	2.7986	.15578
	95% Confidence Interval for Mean	Lower Bound	2.4882
		Upper Bound	3.1089
	5% Trimmed Mean	2.7447	
	Median	2.5850	
	Variance	1.844	
	Std. Deviation	1.35810	
	Minimum	.51	
	Maximum	6.49	
	Range	5.98	
	Interquartile Range	2.12	
	Skewness	.584	.276
	Kurtosis	-.432	.545


Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
kadar HOMA.IR	.088	76	.200*	.954	76	.008

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction








kadar HOMA.IR Stem-and-Leaf Plot

Frequency	Stem & Leaf
2,00	0 . 58
24,00	1 . 001122233333455557777889
19,00	2 . 0111134444556667788
15,00	3 . 000111444466788
10,00	4 . 0223345889
5,00	5 . 12345
1,00	6 . 4

Stem width: 1,00
Each leaf: 1 case(s)







Kadar Gremlin-1

Case Processing Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
kadar GREMLIN-1	76	100.0%	0	0.0%	76	100.0%

Descriptives

		Statistic	Std. Error
kadar GHRELIN	Mean	3.7991	.15409
	95% Confidence Interval for Mean	Lower Bound	3.4921
		Upper Bound	4.1060
	5% Trimmed Mean	3.7687	
	Median	3.7550	
	Variance	1.804	
	Std. Deviation	1.34328	
	Minimum	1.30	
	Maximum	7.28	
	Range	5.98	
	Interquartile Range	2.20	
	Skewness	.244	.276
	Kurtosis	-.621	.545


Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
kadar GREMLIN-1	.073	76	.200*	.977	76	.187

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction








kadar GHRELIN Stem-and-Leaf Plot

Frequency	Stem &	Leaf
6,00	1 .	368899
17,00	2 .	00011111335566899
21,00	3 .	12222334444556688999
16,00	4 .	2222333455666899
11,00	5 .	00111236679
4,00	6 .	0123
1,00	7 .	2

Stem width: 1,00
Each leaf: 1 case(s)







TABEL 1

Jenis kelamin

Statistics

Jenis Kelamin

N	Valid	76
	Missing	0

		Jenis Kelamin			Cumulative
		Frequency	Percent	Valid Percent	Percent
Valid	Laki-laki	36	47.4	47.4	47.4
	Perempuan	40	52.6	52.6	100.0
	Total	76	100.0	100.0	

Umur

Statistics

Umur

N	Valid	76
	Missing	0
Mean		32.18
Std. Error of Mean		.577
Median		33.00
Mode		32 ^a
Std. Deviation		5.030
Variance		25.299
Range		21
Minimum		19
Maximum		40
Sum		2446

a. Multiple modes exist. The

wn



		Umur			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	19	1	1.3	1.3	1.3
	20	2	2.6	2.6	3.9
	21	1	1.3	1.3	5.3
	22	2	2.6	2.6	7.9
	23	1	1.3	1.3	9.2
	24	1	1.3	1.3	10.5
	26	2	2.6	2.6	13.2
	27	2	2.6	2.6	15.8
	28	2	2.6	2.6	18.4
	29	3	3.9	3.9	22.4
	30	5	6.6	6.6	28.9
	31	5	6.6	6.6	35.5
	32	8	10.5	10.5	46.1
	33	8	10.5	10.5	56.6
	34	8	10.5	10.5	67.1
	35	6	7.9	7.9	75.0
	36	3	3.9	3.9	78.9
	37	5	6.6	6.6	85.5
	38	5	6.6	6.6	92.1
	39	4	5.3	5.3	97.4
	40	2	2.6	2.6	100.0
Total		76	100.0	100.0	

		Umur			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<25 tahun	9	11.8	11.8	11.8
		8	10.5	10.5	22.4
		40	52.6	52.6	75.0
		19	25.0	25.0	100.0
		76	100.0	100.0	



Jenis kelamin

Statistics

IMT

N	Valid	76
	Missing	0
Mean		26.874
Std. Error of Mean		.5983
Median		27.600
Mode		21.4 ^a
Std. Deviation		5.2155
Variance		27.201
Range		21.2
Minimum		18.2
Maximum		39.4
Sum		2042.4

a. Multiple modes exist. The smallest value is shown

IMT

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	18.2	1	1.3	1.3	1.3
	18.3	1	1.3	1.3	2.6
	18.4	1	1.3	1.3	3.9
	18.5	1	1.3	1.3	5.3
	18.7	1	1.3	1.3	6.6
	19.0	1	1.3	1.3	7.9
	19.6	1	1.3	1.3	9.2
		1	1.3	1.3	10.5
		1	1.3	1.3	11.8
		1	1.3	1.3	13.2
		1	1.3	1.3	14.5
		1	1.3	1.3	15.8



20.7	1	1.3	1.3	17.1
20.8	1	1.3	1.3	18.4
21.4	2	2.6	2.6	21.1
21.6	1	1.3	1.3	22.4
21.7	1	1.3	1.3	23.7
21.9	1	1.3	1.3	25.0
22.3	1	1.3	1.3	26.3
22.7	1	1.3	1.3	27.6
22.8	2	2.6	2.6	30.3
23.3	2	2.6	2.6	32.9
23.6	1	1.3	1.3	34.2
23.8	1	1.3	1.3	35.5
24.2	1	1.3	1.3	36.8
24.5	1	1.3	1.3	38.2
25.3	2	2.6	2.6	40.8
25.6	1	1.3	1.3	42.1
26.3	1	1.3	1.3	43.4
27.0	1	1.3	1.3	44.7
27.1	2	2.6	2.6	47.4
27.4	1	1.3	1.3	48.7
27.5	1	1.3	1.3	50.0
27.7	1	1.3	1.3	51.3
28.0	1	1.3	1.3	52.6
28.1	1	1.3	1.3	53.9
28.2	1	1.3	1.3	55.3
28.5	1	1.3	1.3	56.6
28.7	2	2.6	2.6	59.2
28.8	1	1.3	1.3	60.5
29.0	1	1.3	1.3	61.8
29.4	2	2.6	2.6	64.5
29.5	1	1.3	1.3	65.8
29.8	2	2.6	2.6	68.4
30.2	2	2.6	2.6	71.1
	1	1.3	1.3	72.4
	1	1.3	1.3	73.7
	1	1.3	1.3	75.0
	2	2.6	2.6	77.6
	1	1.3	1.3	78.9

31.4	1	1.3	1.3	80.3
31.6	1	1.3	1.3	81.6
32.5	1	1.3	1.3	82.9
32.6	1	1.3	1.3	84.2
32.8	1	1.3	1.3	85.5
33.1	1	1.3	1.3	86.8
33.2	2	2.6	2.6	89.5
33.3	1	1.3	1.3	90.8
33.6	1	1.3	1.3	92.1
33.9	1	1.3	1.3	93.4
34.2	2	2.6	2.6	96.1
35.7	2	2.6	2.6	98.7
39.4	1	1.3	1.3	100.0
Total	76	100.0	100.0	

Obesitas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Non Obesitas	30	39.5	39.5	39.5
	Obesitas	46	60.5	60.5	100.0
	Total	76	100.0	100.0	



Kadar Insulin

Statistics

Kadar Insulin

N	Valid	76
	Missing	0
Mean		11.7334
Std. Error of Mean		.61903
Median		11.0350
Mode		9.49 ^a
Std. Deviation		5.39660
Variance		29.123
Range		20.73
Minimum		2.74
Maximum		23.47
Sum		891.74

a. Multiple modes exist. The smallest value is shown

Kadar GDP

Statistics

Kadar GDP

N	Valid	76
	Missing	0
Mean		95.67
Std. Error of Mean		.994
Median		95.00
Mode		92 ^a
Std. Deviation		8.669
Variance		75.157
Range		39
Minimum		75
Maximum		114
Sum		7271



a. Multiple modes exist. The smallest value is shown

Kadar GDP					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	75	2	2.6	2.6	2.6
	78	2	2.6	2.6	5.3
	85	2	2.6	2.6	7.9
	86	2	2.6	2.6	10.5
	87	4	5.3	5.3	15.8
	88	2	2.6	2.6	18.4
	89	4	5.3	5.3	23.7
	90	1	1.3	1.3	25.0
	91	1	1.3	1.3	26.3
	92	8	10.5	10.5	36.8
	93	8	10.5	10.5	47.4
	94	1	1.3	1.3	48.7
	95	4	5.3	5.3	53.9
	96	3	3.9	3.9	57.9
	97	2	2.6	2.6	60.5
	98	5	6.6	6.6	67.1
	99	2	2.6	2.6	69.7
	100	3	3.9	3.9	73.7
	102	2	2.6	2.6	76.3
	103	3	3.9	3.9	80.3
	104	1	1.3	1.3	81.6
	105	3	3.9	3.9	85.5
	106	2	2.6	2.6	88.2
	107	1	1.3	1.3	89.5
	108	3	3.9	3.9	93.4
	110	1	1.3	1.3	94.7
		1	1.3	1.3	96.1
		1	1.3	1.3	97.4
		2	2.6	2.6	100.0
		76	100.0	100.0	



Kadar Gremlin-1

Statistics

kadar GHRELIN

N	Valid	76
	Missing	0
Mean		3.7991
Std. Error of Mean		.15409
Median		3.7550
Mode		2.17 ^a
Std. Deviation		1.34328
Variance		1.804
Range		5.98
Minimum		1.30
Maximum		7.28
Sum		288.73

a. Multiple modes exist. The smallest value is shown

kadar GREMLIN-1

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	1.30	1	1.3	1.3	1.3
	1.60	1	1.3	1.3	2.6
	1.84	1	1.3	1.3	3.9
	1.86	1	1.3	1.3	5.3
	1.94	1	1.3	1.3	6.6
	1.98	1	1.3	1.3	7.9
	2.05	1	1.3	1.3	9.2
	2.06	1	1.3	1.3	10.5
	2.07	1	1.3	1.3	11.8
	2.11	1	1.3	1.3	13.2
		2	2.6	2.6	15.8
		1	1.3	1.3	17.1
		1	1.3	1.3	18.4
		1	1.3	1.3	19.7



2.33	1	1.3	1.3	21.1
2.55	1	1.3	1.3	22.4
2.58	1	1.3	1.3	23.7
2.62	1	1.3	1.3	25.0
2.65	1	1.3	1.3	26.3
2.86	1	1.3	1.3	27.6
2.93	1	1.3	1.3	28.9
2.95	1	1.3	1.3	30.3
3.15	1	1.3	1.3	31.6
3.20	1	1.3	1.3	32.9
3.21	1	1.3	1.3	34.2
3.23	1	1.3	1.3	35.5
3.24	1	1.3	1.3	36.8
3.32	1	1.3	1.3	38.2
3.33	1	1.3	1.3	39.5
3.42	1	1.3	1.3	40.8
3.43	2	2.6	2.6	43.4
3.46	1	1.3	1.3	44.7
3.55	1	1.3	1.3	46.1
3.57	1	1.3	1.3	47.4
3.64	1	1.3	1.3	48.7
3.66	1	1.3	1.3	50.0
3.85	2	2.6	2.6	52.6
3.86	1	1.3	1.3	53.9
3.90	2	2.6	2.6	56.6
3.91	1	1.3	1.3	57.9
4.20	1	1.3	1.3	59.2
4.23	1	1.3	1.3	60.5
4.27	2	2.6	2.6	63.2
4.32	1	1.3	1.3	64.5
4.36	1	1.3	1.3	65.8
4.39	1	1.3	1.3	67.1
4.49	1	1.3	1.3	68.4
	1	1.3	1.3	69.7
	1	1.3	1.3	71.1
	1	1.3	1.3	72.4
	1	1.3	1.3	73.7
	1	1.3	1.3	75.0



4.88	1	1.3	1.3	76.3
4.93	1	1.3	1.3	77.6
4.98	1	1.3	1.3	78.9
5.01	1	1.3	1.3	80.3
5.06	1	1.3	1.3	81.6
5.10	1	1.3	1.3	82.9
5.11	1	1.3	1.3	84.2
5.13	1	1.3	1.3	85.5
5.23	1	1.3	1.3	86.8
5.32	1	1.3	1.3	88.2
5.63	1	1.3	1.3	89.5
5.65	1	1.3	1.3	90.8
5.76	1	1.3	1.3	92.1
5.94	1	1.3	1.3	93.4
6.03	1	1.3	1.3	94.7
6.12	1	1.3	1.3	96.1
6.20	1	1.3	1.3	97.4
6.35	1	1.3	1.3	98.7
7.28	1	1.3	1.3	100.0
Total	76	100.0	100.0	



Nilai HOMA.IR

Statistics

kadar HOMA.IR

N	Valid	76
	Missing	0
Mean		2.7986
Std. Error of Mean		.15578
Median		2.5850
Mode		1.38 ^a
Std. Deviation		1.35810
Variance		1.844
Range		5.98
Minimum		.51
Maximum		6.49
Sum		212.69

a. Multiple modes exist. The
smallest value is shown

kadar HOMA.IR

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	.51	1	1.3	1.3	1.3
	.81	1	1.3	1.3	2.6
	1.05	1	1.3	1.3	3.9
	1.07	1	1.3	1.3	5.3
	1.15	1	1.3	1.3	6.6
	1.19	1	1.3	1.3	7.9
	1.26	1	1.3	1.3	9.2
	1.27	1	1.3	1.3	10.5
	1.28	1	1.3	1.3	11.8
	1.32	1	1.3	1.3	13.2
		1	1.3	1.3	14.5
		2	2.6	2.6	17.1
		1	1.3	1.3	18.4
		1	1.3	1.3	19.7



1.51	1	1.3	1.3	21.1
1.53	1	1.3	1.3	22.4
1.54	1	1.3	1.3	23.7
1.57	1	1.3	1.3	25.0
1.70	1	1.3	1.3	26.3
1.76	2	2.6	2.6	28.9
1.79	1	1.3	1.3	30.3
1.83	1	1.3	1.3	31.6
1.86	1	1.3	1.3	32.9
1.90	1	1.3	1.3	34.2
2.07	1	1.3	1.3	35.5
2.14	2	2.6	2.6	38.2
2.16	1	1.3	1.3	39.5
2.19	1	1.3	1.3	40.8
2.36	1	1.3	1.3	42.1
2.41	1	1.3	1.3	43.4
2.42	1	1.3	1.3	44.7
2.44	1	1.3	1.3	46.1
2.45	1	1.3	1.3	47.4
2.53	1	1.3	1.3	48.7
2.54	1	1.3	1.3	50.0
2.63	1	1.3	1.3	51.3
2.64	1	1.3	1.3	52.6
2.67	1	1.3	1.3	53.9
2.76	1	1.3	1.3	55.3
2.78	1	1.3	1.3	56.6
2.85	1	1.3	1.3	57.9
2.87	1	1.3	1.3	59.2
3.06	2	2.6	2.6	61.8
3.07	1	1.3	1.3	63.2
3.11	2	2.6	2.6	65.8
3.12	1	1.3	1.3	67.1
3.41	1	1.3	1.3	68.4
	1	1.3	1.3	69.7
	2	2.6	2.6	72.4
	1	1.3	1.3	73.7
	1	1.3	1.3	75.0
	1	1.3	1.3	76.3

3.84	1	1.3	1.3	77.6
3.89	1	1.3	1.3	78.9
4.09	1	1.3	1.3	80.3
4.22	1	1.3	1.3	81.6
4.27	1	1.3	1.3	82.9
4.31	1	1.3	1.3	84.2
4.32	1	1.3	1.3	85.5
4.44	1	1.3	1.3	86.8
4.53	1	1.3	1.3	88.2
4.84	1	1.3	1.3	89.5
4.86	1	1.3	1.3	90.8
4.97	1	1.3	1.3	92.1
5.15	1	1.3	1.3	93.4
5.24	1	1.3	1.3	94.7
5.33	1	1.3	1.3	96.1
5.41	1	1.3	1.3	97.4
5.56	1	1.3	1.3	98.7
6.49	1	1.3	1.3	100.0
Total	76	100.0	100.0	



TABEL 2

Jenis kelamin

Statistics

Jenis Kelamin Obesitas Non

Obesitas

N	Valid	76
	Missing	0
Mean		2.45
Std. Error of Mean		.134
Median		3.00
Mode		1
Std. Deviation		1.171
Variance		1.371
Range		3
Minimum		1
Maximum		4
Sum		186

Jenis Kelamin Obesitas Non Obesitas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki obes	24	31.6	31.6	31.6
	Laki-laki non obes	12	15.8	15.8	47.4
	Perempuan obes	22	28.9	28.9	76.3
	Perempuan non obes	18	23.7	23.7	100.0
	Total	76	100.0	100.0	



Umur

Statistics

Umur Obesitas

N	Valid	46
	Missing	0
Mean		32.41
Std. Error of Mean		.672
Median		33.00
Mode		32
Std. Deviation		4.559
Variance		20.781
Range		19
Minimum		20
Maximum		39
Sum		1491

Umur Obesitas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	20	1	2.2	2.2	2.2
	21	1	2.2	2.2	4.3
	22	1	2.2	2.2	6.5
	23	1	2.2	2.2	8.7
	27	1	2.2	2.2	10.9
	28	2	4.3	4.3	15.2
	29	1	2.2	2.2	17.4
	30	3	6.5	6.5	23.9
	31	4	8.7	8.7	32.6
	32	7	15.2	15.2	47.8
	33	5	10.9	10.9	58.7
	34	4	8.7	8.7	67.4
	35	3	6.5	6.5	73.9
	36	3	6.5	6.5	80.4
	37	4	8.7	8.7	89.1
	38	2	4.3	4.3	93.5
	39	3	6.5	6.5	100.0



Total	46	100.0	100.0
-------	----	-------	-------

Statistics

Umur Non Obesitas

N	Valid	30
	Missing	0
Mean		31.83
Std. Error of Mean		1.048
Median		33.00
Mode		34
Std. Deviation		5.742
Variance		32.971
Range		21
Minimum		19
Maximum		40
Sum		955

Umur Non Obesitas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	19	1	3.3	3.3	3.3
	20	1	3.3	3.3	6.7
	22	1	3.3	3.3	10.0
	24	1	3.3	3.3	13.3
	26	2	6.7	6.7	20.0
	27	1	3.3	3.3	23.3
	29	2	6.7	6.7	30.0
	30	2	6.7	6.7	36.7
	31	1	3.3	3.3	40.0
	32	1	3.3	3.3	43.3
	33	3	10.0	10.0	53.3
	34	4	13.3	13.3	66.7
	35	3	10.0	10.0	76.7
		1	3.3	3.3	80.0
		3	10.0	10.0	90.0
		1	3.3	3.3	93.3
		2	6.7	6.7	100.0
		30	100.0	100.0	



Kadar Insulin

Statistics

Kadar Insulin

N	Valid	46
	Missing	0
Mean		14.0035
Std. Error of Mean		.77621
Median		14.0200
Mode		5.36 ^a
Std. Deviation		5.26450
Variance		27.715
Range		18.11
Minimum		5.36
Maximum		23.47
Sum		644.16

a. Multiple modes exist. The smallest value is shown

Kadar Insulin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	5.36	1	2.2	2.2	2.2
	6.40	1	2.2	2.2	4.3
	6.52	1	2.2	2.2	6.5
	7.27	1	2.2	2.2	8.7
	7.48	1	2.2	2.2	10.9
	7.74	1	2.2	2.2	13.0
	8.03	1	2.2	2.2	15.2
	8.11	1	2.2	2.2	17.4
	8.17	1	2.2	2.2	19.6
	8.47	1	2.2	2.2	21.7
		1	2.2	2.2	23.9
		1	2.2	2.2	26.1
		1	2.2	2.2	28.3
		1	2.2	2.2	30.4



10.27	1	2.2	2.2	32.6
10.42	1	2.2	2.2	34.8
11.02	1	2.2	2.2	37.0
11.58	1	2.2	2.2	39.1
11.88	1	2.2	2.2	41.3
12.23	1	2.2	2.2	43.5
13.37	1	2.2	2.2	45.7
13.75	1	2.2	2.2	47.8
13.82	1	2.2	2.2	50.0
14.22	1	2.2	2.2	52.2
14.26	1	2.2	2.2	54.3
14.52	1	2.2	2.2	56.5
15.31	1	2.2	2.2	58.7
15.79	1	2.2	2.2	60.9
15.86	1	2.2	2.2	63.0
16.04	1	2.2	2.2	65.2
17.06	1	2.2	2.2	67.4
17.14	1	2.2	2.2	69.6
17.19	1	2.2	2.2	71.7
17.27	1	2.2	2.2	73.9
18.31	1	2.2	2.2	76.1
18.78	1	2.2	2.2	78.3
18.83	1	2.2	2.2	80.4
19.35	1	2.2	2.2	82.6
19.38	1	2.2	2.2	84.8
19.91	1	2.2	2.2	87.0
21.44	1	2.2	2.2	89.1
21.90	1	2.2	2.2	91.3
22.62	1	2.2	2.2	93.5
23.06	1	2.2	2.2	95.7
23.23	1	2.2	2.2	97.8
23.47	1	2.2	2.2	100.0
Total	46	100.0	100.0	



Statistics

Kadar Insulin

N	Valid	30
	Missing	0
Mean		8.2527
Std. Error of Mean		.62197
Median		7.2150
Mode		9.49 ^a
Std. Deviation		3.40668
Variance		11.605
Range		11.30
Minimum		2.74
Maximum		14.04
Sum		247.58

a. Multiple modes exist. The smallest value is shown

Kadar Insulin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	2.74	1	3.3	3.3	3.3
	4.22	1	3.3	3.3	6.7
	4.33	1	3.3	3.3	10.0
	4.92	1	3.3	3.3	13.3
	4.94	1	3.3	3.3	16.7
	5.18	1	3.3	3.3	20.0
	5.50	1	3.3	3.3	23.3
	5.53	1	3.3	3.3	26.7
	5.68	1	3.3	3.3	30.0
	5.83	1	3.3	3.3	33.3
	5.90	1	3.3	3.3	36.7
	5.97	1	3.3	3.3	40.0
		1	3.3	3.3	43.3
		1	3.3	3.3	46.7
		1	3.3	3.3	50.0
		1	3.3	3.3	53.3
		1	3.3	3.3	56.7



8.67	1	3.3	3.3	60.0
9.49	2	6.7	6.7	66.7
9.76	1	3.3	3.3	70.0
11.05	1	3.3	3.3	73.3
11.46	1	3.3	3.3	76.7
11.78	1	3.3	3.3	80.0
12.53	1	3.3	3.3	83.3
13.15	2	6.7	6.7	90.0
13.70	2	6.7	6.7	96.7
14.04	1	3.3	3.3	100.0
Total	30	100.0	100.0	



Kadar GDP

Statistics

Kadar GDP Obesitas

N	Valid	46
	Missing	0
Mean		96.65
Std. Error of Mean		1.301
Median		94.00
Mode		92
Std. Deviation		8.825
Variance		77.876
Range		39
Minimum		75
Maximum		114
Sum		4446

Kadar GDP Obesitas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	75	1	2.2	2.2	2.2
	85	1	2.2	2.2	4.3
	86	1	2.2	2.2	6.5
	87	3	6.5	6.5	13.0
	88	1	2.2	2.2	15.2
	89	3	6.5	6.5	21.7
	90	1	2.2	2.2	23.9
	91	1	2.2	2.2	26.1
	92	6	13.0	13.0	39.1
	93	5	10.9	10.9	50.0
	95	1	2.2	2.2	52.2
	96	2	4.3	4.3	56.5
		2	4.3	4.3	60.9
		2	4.3	4.3	65.2
		1	2.2	2.2	67.4
		2	4.3	4.3	71.7



103	2	4.3	4.3	76.1
105	2	4.3	4.3	80.4
106	2	4.3	4.3	84.8
107	1	2.2	2.2	87.0
108	1	2.2	2.2	89.1
110	1	2.2	2.2	91.3
112	1	2.2	2.2	93.5
113	1	2.2	2.2	95.7
114	2	4.3	4.3	100.0
Total	46	100.0	100.0	

Statistics

Kadar GDP Non Obesitas

N	Valid	30
	Missing	0
Mean		94.17
Std. Error of Mean		1.524
Median		95.00
Mode		93 ^a
Std. Deviation		8.346
Variance		69.661
Range		33
Minimum		75
Maximum		108
Sum		2825

a. Multiple modes exist. The smallest value is shown

Kadar GDP Non Obesitas

	Frequency	Percent	Valid Percent	Cumulative Percent
1	1	3.3	3.3	3.3
2	2	6.7	6.7	10.0
3	1	3.3	3.3	13.3
4	1	3.3	3.3	16.7
5	1	3.3	3.3	20.0



88	1	3.3	3.3	23.3
89	1	3.3	3.3	26.7
92	2	6.7	6.7	33.3
93	3	10.0	10.0	43.3
94	1	3.3	3.3	46.7
95	3	10.0	10.0	56.7
96	1	3.3	3.3	60.0
98	3	10.0	10.0	70.0
99	1	3.3	3.3	73.3
100	3	10.0	10.0	83.3
103	1	3.3	3.3	86.7
104	1	3.3	3.3	90.0
105	1	3.3	3.3	93.3
108	2	6.7	6.7	100.0
Total	30	100.0	100.0	

Kadar gremlin-1

Statistics

kadar Gremlin-1 Obesitas

N	Valid	46
	Missing	0
Mean		4.5541
Std. Error of Mean		.15980
Median		4.5450
Mode		4.27
Std. Deviation		1.08384
Variance		1.175
Range		5.21
Minimum		2.07
Maximum		7.28
Sum		209.49



kadar GREMLIN-1 Obesitas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	2.07	1	2.2	2.2	2.2
	2.55	1	2.2	2.2	4.3
	2.86	1	2.2	2.2	6.5
	3.15	1	2.2	2.2	8.7
	3.21	1	2.2	2.2	10.9
	3.24	1	2.2	2.2	13.0
	3.33	1	2.2	2.2	15.2
	3.42	1	2.2	2.2	17.4
	3.43	1	2.2	2.2	19.6
	3.57	1	2.2	2.2	21.7
	3.66	1	2.2	2.2	23.9
	3.86	1	2.2	2.2	26.1
	3.90	1	2.2	2.2	28.3
	3.91	1	2.2	2.2	30.4
	4.20	1	2.2	2.2	32.6
	4.23	1	2.2	2.2	34.8
	4.27	2	4.3	4.3	39.1
	4.32	1	2.2	2.2	41.3
	4.36	1	2.2	2.2	43.5
	4.39	1	2.2	2.2	45.7
	4.49	1	2.2	2.2	47.8
	4.54	1	2.2	2.2	50.0
	4.55	1	2.2	2.2	52.2
	4.63	1	2.2	2.2	54.3
	4.68	1	2.2	2.2	56.5
	4.69	1	2.2	2.2	58.7
	4.88	1	2.2	2.2	60.9
	4.93	1	2.2	2.2	63.0
	4.98	1	2.2	2.2	65.2
	5.01	1	2.2	2.2	67.4
		1	2.2	2.2	69.6
		1	2.2	2.2	71.7
		1	2.2	2.2	73.9
		1	2.2	2.2	76.1
		1	2.2	2.2	78.3



5.32	1	2.2	2.2	80.4
5.63	1	2.2	2.2	82.6
5.65	1	2.2	2.2	84.8
5.76	1	2.2	2.2	87.0
5.94	1	2.2	2.2	89.1
6.03	1	2.2	2.2	91.3
6.12	1	2.2	2.2	93.5
6.20	1	2.2	2.2	95.7
6.35	1	2.2	2.2	97.8
7.28	1	2.2	2.2	100.0
Total	46	100.0	100.0	

Statistics

kadar GREMLIN-1 Non Obesitas

N	Valid	30
	Missing	0
Mean		2.6413
Std. Error of Mean		.13575
Median		2.4550
Mode		2.17 ^a
Std. Deviation		.74355
Variance		.553
Range		2.60
Minimum		1.30
Maximum		3.90
Sum		79.24

a. Multiple modes exist. The smallest value is shown

kadar GREMLIN-1 Non Obesitas



frequency	Percent	Valid Percent	Cumulative Percent
1	3.3	3.3	3.3
1	3.3	3.3	6.7

1.84	1	3.3	3.3	10.0
1.86	1	3.3	3.3	13.3
1.94	1	3.3	3.3	16.7
1.98	1	3.3	3.3	20.0
2.05	1	3.3	3.3	23.3
2.06	1	3.3	3.3	26.7
2.11	1	3.3	3.3	30.0
2.17	2	6.7	6.7	36.7
2.18	1	3.3	3.3	40.0
2.19	1	3.3	3.3	43.3
2.30	1	3.3	3.3	46.7
2.33	1	3.3	3.3	50.0
2.58	1	3.3	3.3	53.3
2.62	1	3.3	3.3	56.7
2.65	1	3.3	3.3	60.0
2.93	1	3.3	3.3	63.3
2.95	1	3.3	3.3	66.7
3.20	1	3.3	3.3	70.0
3.23	1	3.3	3.3	73.3
3.32	1	3.3	3.3	76.7
3.43	1	3.3	3.3	80.0
3.46	1	3.3	3.3	83.3
3.55	1	3.3	3.3	86.7
3.64	1	3.3	3.3	90.0
3.85	2	6.7	6.7	96.7
3.90	1	3.3	3.3	100.0
Total	30	100.0	100.0	



Nilai HOMA.IR

Statistics

kadar HOMA.IR Obesitas

N	Valid	46
	Missing	0
Mean		3.3587
Std. Error of Mean		.19752
Median		3.2650
Mode		1.76
Std. Deviation		1.33964
Variance		1.795
Range		5.21
Minimum		1.28
Maximum		6.49
Sum		154.50

kadar HOMA.IR Obesitas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	1.28	1	2.2	2.2	2.2
	1.34	1	2.2	2.2	4.3
	1.53	1	2.2	2.2	6.5
	1.54	1	2.2	2.2	8.7
	1.70	1	2.2	2.2	10.9
	1.76	2	4.3	4.3	15.2
	1.86	1	2.2	2.2	17.4
	1.90	1	2.2	2.2	19.6
	2.07	1	2.2	2.2	21.7
	2.14	1	2.2	2.2	23.9
	2.19	1	2.2	2.2	26.1
	2.36	1	2.2	2.2	28.3
		1	2.2	2.2	30.4
		1	2.2	2.2	32.6
		1	2.2	2.2	34.8
		1	2.2	2.2	37.0



2.64	1	2.2	2.2	39.1
2.78	1	2.2	2.2	41.3
2.87	1	2.2	2.2	43.5
3.07	1	2.2	2.2	45.7
3.11	1	2.2	2.2	47.8
3.12	1	2.2	2.2	50.0
3.41	1	2.2	2.2	52.2
3.44	1	2.2	2.2	54.3
3.48	1	2.2	2.2	56.5
3.60	1	2.2	2.2	58.7
3.75	1	2.2	2.2	60.9
3.84	1	2.2	2.2	63.0
3.89	1	2.2	2.2	65.2
4.09	1	2.2	2.2	67.4
4.22	1	2.2	2.2	69.6
4.27	1	2.2	2.2	71.7
4.31	1	2.2	2.2	73.9
4.32	1	2.2	2.2	76.1
4.44	1	2.2	2.2	78.3
4.53	1	2.2	2.2	80.4
4.84	1	2.2	2.2	82.6
4.86	1	2.2	2.2	84.8
4.97	1	2.2	2.2	87.0
5.15	1	2.2	2.2	89.1
5.24	1	2.2	2.2	91.3
5.33	1	2.2	2.2	93.5
5.41	1	2.2	2.2	95.7
5.56	1	2.2	2.2	97.8
6.49	1	2.2	2.2	100.0
Total	46	100.0	100.0	



Statistics

kadar HOMA.IR Non Obesitas

N	Valid	30
	Missing	0
Mean		1.9397
Std. Error of Mean		.15540
Median		1.6800
Mode		1.38 ^a
Std. Deviation		.85118
Variance		.725
Range		3.13
Minimum		.51
Maximum		3.64
Sum		58.19

a. Multiple modes exist. The smallest value is shown

kadar HOMA.IR Non Obesitas

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	.51	1	3.3	3.3	3.3
	.81	1	3.3	3.3	6.7
	1.05	1	3.3	3.3	10.0
	1.07	1	3.3	3.3	13.3
	1.15	1	3.3	3.3	16.7
	1.19	1	3.3	3.3	20.0
	1.26	1	3.3	3.3	23.3
	1.27	1	3.3	3.3	26.7
	1.32	1	3.3	3.3	30.0
	1.38	2	6.7	6.7	36.7
	1.39	1	3.3	3.3	40.0
	1.40	1	3.3	3.3	43.3
		1	3.3	3.3	46.7
		1	3.3	3.3	50.0
		1	3.3	3.3	53.3
		1	3.3	3.3	56.7
		1	3.3	3.3	60.0



2.16	1	3.3	3.3	63.3
2.41	1	3.3	3.3	66.7
2.44	1	3.3	3.3	70.0
2.53	1	3.3	3.3	73.3
2.67	1	3.3	3.3	76.7
2.76	1	3.3	3.3	80.0
2.85	1	3.3	3.3	83.3
3.06	2	6.7	6.7	90.0
3.11	1	3.3	3.3	93.3
3.48	1	3.3	3.3	96.7
3.64	1	3.3	3.3	100.0
Total	30	100.0	100.0	



Tabel 3

Perbedaan Nilai HOMA-IR pada Kelompok Penelitian

Independent Samples Test

Group Statistics

	Obesitas	N	Mean	Std. Deviation	Std. Error Mean
kadar HOMA-IR	Obesitas	46	3.3587	1.33964	.19752
	Non Obesitas	30	1.9397	.85118	.15540


Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference		Lower	Upper
kadar	Equal variances assumed	8.322	.005	5.156	74	.000	1.41903	.27521		.87067	1.96739
HOMA-IR	Equal variances not assumed			5.646	73.972	.000	1.41903	.25132		.91825	1.91981

Berdasarkan tabel output *Independent Samples Test* diketahui nilai sig. adalah $0,000 < 0,05$ dan nilai t hitung $5,156 > 1,99254$ t tabel sehingga dapat disimpulkan bahwa terdapat Perbedaan Nilai HOMA-IR pada Kelompok Penelitian



Simple Line of Obesitas by kadar HOMA.IR



Tabel 4

Perbedaan Kadar Gremlin-1 Serum (ng/mL) pada Kelompok Penelitian

Independent Samples Test

Group Statistics

	Obesitas	N	Mean	Std. Deviation	Std. Error Mean
kadar GHRELIN	Obesitas	46	4.5541	1.08384	.15980
	Non Obesitas	30	2.6413	.74355	.13575


Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference		Lower	Upper
kadar	Equal variances assumed	2.462	.121	8.447	74	.000	1.91280	.22644		1.46161	2.36398
GHRELIN	Equal variances not assumed			9.122	73.770	.000	1.91280	.20968		1.49498	2.33062

Berdasarkan tabel output *Independent Samples Test* diketahui nilai sig. adalah $0,000 < 0,05$ dan nilai t hitung $8,447 > 1,99254$ t tabel sehingga dapat disimpulkan bahwa terdapat Perbedaan Kadar Ghrelin Serum (ng/mL) pada Kelompok Penelitian



Simple Line of Obesitas by kadar GHRELIN



TABEL 5

Hubungan antara kadar HOMA-IR dengan IMT pada Kelompok Penelitian

Descriptive Statistics


	Mean	Std. Deviation	N
kadar HOMA-IR	2.7986	1.35810	76
IMT	26.874	5.2155	76

Correlations

		kadar HOMA-IR	IMT
kadar HOMA-IR	Pearson Correlation	1	.535**
	Sig. (2-tailed)		.000
	N	76	76
IMT	Pearson Correlation	.535**	1
	Sig. (2-tailed)	.000	
	N	76	76

** . Correlation is significant at the 0.01 level (2-tailed).

Simple Line of IMT by kadar HOMA-IR



TABEL 6

Hubungan antara kadar Gremlin dengan IMT pada Kelompok Penelitian

Descriptive Statistics


	Mean	Std. Deviation	N
kadar GHRELIN	3.7991	1.34328	76
IMT	26.874	5.2155	76

Correlations

		kadar GHRELIN	IMT
kadar GHRELIN	Pearson Correlation	1	.588**
	Sig. (2-tailed)		.000
	N	76	76
IMT	Pearson Correlation	.588**	1
	Sig. (2-tailed)	.000	
	N	76	76

** . Correlation is significant at the 0.01 level (2-tailed).

Simple Line of IMT by kadar GHRELIN



TABEL 7

Hubungan antara kadar HOMA.IR dan Gremlin-1 pada Kelompok Penelitian

Gabungan Obesitas dan Non Obesitas

Descriptive Statistics


	Mean	Std. Deviation	N
kadar HOMA.IR	2.7986	1.35810	76
kadar GREMLIN-1	3.7991	1.34328	76

Correlations

		kadar HOMA.IR	kadar GHRELIN
kadar HOMA.IR	Pearson Correlation	1	.781**
	Sig. (2-tailed)		.000
	N	76	76
kadar GREMLIN-1	Pearson Correlation	.781**	1
	Sig. (2-tailed)	.000	
	N	76	76

** . Correlation is significant at the 0.01 level (2-tailed).

Simple Line of kadar GHRELIN by kadar HOMA.IR




Obesitas

Correlations

		kadar HOMA.IR Obesitas	kadar GHRELIN Obesitas
kadar HOMA.IR Obesitas	Pearson Correlation	1	.628**
	Sig. (2-tailed)		.000
	N	46	46
kadar GREMLIN-1Obesitas	Pearson Correlation	.628**	1
	Sig. (2-tailed)	.000	
	N	46	46

** . Correlation is significant at the 0.01 level (2-tailed).

Simple Line of kadar GHRELIN Obesitas by kadar HOMA.IR Obesitas



Non Obesitas

Correlations


		kadar HOMA.IR Non Obesitas	kadar GHRELIN Non Obesitas
HOMA.IR Non	Pearson Correlation	1	.901**
	Sig. (2-tailed)		.000
	N	30	30
GREMLIN-1Non	Pearson Correlation	.901**	1
	Sig. (2-tailed)	.000	



N	30	30
---	----	----

** . Correlation is significant at the 0.01 level (2-tailed).

Simple Line Mean of kadar GHRELIN Non Obesitas by kadar HOMA.IR Non Obesitas



Lampiran 2. REKOMENDASI PERSETUJUAN ETIK



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agusnalin Bulharli, MMed, PhD, SpCA, TELP. 081241850858, 0411 5790103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 792/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 16 Oktober 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23090704	No Sponsor	
Peneliti Utama	dr. Reskiana Syahrir	Sponsor	
Judul Peneliti	Korelasi kadar Gremlin-1 serum dengan resistensi insulin pada subjek non Diabetes Melitus		
No Versi Protokol	1	Tanggal Versi	18 September 2023
No Versi PSP	1	Tanggal Versi	18 September 2023
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 16 Oktober 2023 sampai 16 Oktober 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Lampiran 3. NASKAH PENJELASAN UNTUK RESPONDEN (SUBJEK)



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN

KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN

RSPTN UNIVERSITAS HASANUDDIN

RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



FORMULIR PERSETUJUAN SETELAH PENJELASAN (PSP) (INFORMED CONSENT)

Selamat pagi Bapak / Ibu /Saudara(i), saya dr. Reskiana Syahrir bermaksud untuk melakukan penelitian Korelasi Kadar Gremlin-1 serum dengan Resistensi Insulin pada Subjek Non Diabetes Melitus.

Saya akan melakukan penelitian dengan menganalisis korelasi kadar Gremlin-1 serum dengan resistensi insulin pada subjek non Diabetes Melitus yang bertujuan untuk mengetahui apakah ada hubungan antara Gremlin-1 dan resistensi insulin pada subjek obesitas dan non obesitas tanpa diabetes melitus. Manfaat yang dapat diambil dari aspek klinis adalah dapat menjadi bahan pertimbangan bagi para klinisi dalam menangani resistensi insulin pada non diabetes melitus sehingga dapat mencegah dan menurunkan insidensi diabetes melitus dan komplikasinya.

Adapun penelitian ini tidak memaksa keikutsertaan Bapak / Ibu / saudara (i) dan jika Bapak / Ibu / saudara (i) bersedia menandatangani formulir kesediaan ikut serta dalam penelitian dengan sukarela. Bapak / Ibu / saudara (i) tidak perlu khawatir ketidakikutsertaan anda dalam penelitian ini tidak mengurangi pelayanan kesehatan yang diperoleh dari pihak rumah sakit. Prosedur yang akan kami lakukan adalah pengambilan sampel darah melalui pembuluh darah di bagian lengan dengan menggunakan jarum. Sampel darah diambil sebanyak minimal 3 cc. Risiko yang mungkin terjadi saat pengambilan darah berupa kebiruan di daerah suntikan. Hal ini bisa diatasi dengan cara menekan perlahan-lahan mengkilang. Cara penanganan jika terjadi kebiruan



adalah mengompres dengan air dingin, membalut. Bila terjadi perdarahan di area bekas suntikan, dapat dilakukan penekanan guna menghentikan perdarahan dan mengangkat bagian tubuh lebih tinggi dari jantung untuk mengurangi aliran darah ke daerah yang mengalami perdarahan. Penelitian ini tidak dipungut bayaran sama sekali. Sampel darah dimasukkan ke dalam tabung kecil khusus lalu dibawa ke laboratorium untuk dilakukan pemeriksaan Gremlin-1 serum dan kadar insulin.

Kami menjamin keamanan dan kerahasiaan semua data pada penelitian ini. Data akan disimpan dengan baik dan aman sehingga hanya bisa dilihat oleh yang berkepentingan saja. Data pribadi disamarkan pada semua catatan dan pada pelaporan baik lisan ataupun tertulis tidak akan menggunakan data pribadi. Jika ada hal yang ingin ditanyakan mengenai penelitian ini dapat menghubungi peneliti dengan alamat dan nomor kontak di bawah ini

IdentitasPeneliti:

Nama : dr. Reskiana Syahrir

Alamat: jl Maccini Raya No 206

No Hp : 0811461988



Lampiran 4. FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN

**KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN**



**KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN**



RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

**JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10
MAKASSAR 90245.**

**Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858,
0411 5780103, Fax : 0411-581431**

FORMULIR PERSETUJUAN SETELAH PENJELASAN

**Judul Penelitian : Korelasi Kadar Gremlin-1 Serum dengan Resistensi Insulin
pada Subjek Non Diabetes Melitus**

Saya yang bertandatangan di bawah ini :

Nama :

Umur :

Masa Kerja :

Satuan :

Alamat :

.....

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat, dan apa yang akan dilakukan pada penelitian ini, menyatakan setuju untuk ikut dalam penelitian ini secara sukarela tanpa paksaan.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, saya bisa menolak ikut atau mengundurkan diri dari penelitian ini. Saya bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang atau masih ada hal yang ingin saya ketahui tentang penelitian ini.



Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti. Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data saya yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Dengan membubuhkan tandatangan saya di bawah ini, saya menegaskan keikutsertaan saya secara sukarela dalam studi penelitian ini.

Nama	Tanda tangan	Tgl/Bln/Thn
Responden		
/Wali		
Saksi		

Penanggung jawab penelitian :

Nama : dr. Reskiana Syahrir
Alamat : Jl. Maccini Raya No 206.
Tlp : 0811461988

Penanggung jawab Medis :

Dr. dr. Tenri Esa, MSi, Sp.PK (K)
Jl. Bunaken No 16, Bukit Baruga
081524931965



LAMPIRAN 5. BIODATA PENELITI UTAMA

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN



KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN

RSPTN UNIVERSITAS HASANUDDIN

RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari., MMed, PhD, SpGK TELP. 081241850858, 0411
5780103, Fax : 0411-581431



BIODATA PENELITI UTAMA

A. Identitas Diri

1	Nama Lengkap (dengan gelar)	dr. Reskiana Syahrir
2	Tempat dan Tanggal Lahir	Makassar, 4 November 1988
3	E-mail	reskianasyahrir08@gmail.com
4	Alamat Rumah	Jl Maccini Raya No 206
5	Nomor Telepon/HP	0811461988
6	Status	PPDS Ilmu Patologi Klinik FK Unhas

B. Riwayat Pendidikan

	S-1	S-2
Nama Perguruan Tinggi	Universitas Hasanuddin	
Bidang Ilmu	Kedokteran	
Tahun Masuk-Lulus	2006 - 2012	
Judul Skripsi/Thesis/Disertasi	Hubungan Status Gizi Asiswa SD Negeri I Benteng Kepulauan Selayar	
Pengantar/Promotor	1. dr. A. Yasmin Syauki, Msc, Sp.GK 2. dr. Irwin Aras, M.Epid, M.MedEd	



	3. dr. Sri Asriyani, Sp.Rad	
Nama Perguruan Tinggi		
Bidang Ilmu		
Tahun Masuk-Lulus		
Judul Skripsi/Thesis/Disertasi		
Nama Pembimbing/Promotor		

C. Pengalaman Penelitian Dalam 5 Tahun Terakhir
(Bukan Skripsi, Tesis, maupun Disertasi)

No.	Tahun	Judul Penelitian	Pendanaan	
			Sumber*	Jumlah (Rp)
1.	2022	Analisis Kadar Vaspin pada Subjek Obesitas dan Non Obesitas	Pribadi	Rp. 13.500.000
2.	-			
3.	-			

D. Pengalaman Pengabdian Kepada Masyarakat Dalam 5 Tahun Terakhir

No.	Tahun	Judul Pengabdian Kepada Masyarakat	Pendanaan	
			Sumber	Jumlah (Rp)
1.				-
2.				
3.				-
4.				,-
5.				-



E. Publikasi Artikel Ilmiah Dalam Jurnal dalam 5 Tahun Terakhir

No.	Judul Artikel Ilmiah	Volume/ Nomor/Tahun	Nama Jurnal
1.	Analisis Kadar Vaspin pada Subjek Obesitas dan Non Obesitas	Vol. 30 / Nomor 1/ November 2023	Indonesian Journal of Clinical Pathology and Medical Laboratory
2.	-		

F. Pemakalah Seminar Ilmiah (*Oral Presentation*) dalam 5 Tahun Terakhir

No.	Nama Pertemuan Ilmiah/Seminar	Judul Artikel Ilmiah	Waktu dan Tempat
1.	2022	Analisis Kadar Vaspin pada Subjek Obesitas dan Non Obesitas	21 Oktober 2022
2			
3			
4			

G. Karya Buku dalam 5 Tahun Terakhir

No.	Judul Buku	Tahun	Jumlah Halaman	Penerbit
1.	-			
2.	-			
3.	-			

Semua data yang saya isikan dan tercantum dalam biodata ini adalah benar dan dapat dipertanggungjawabkan secara hukum. Apabila di kemudian hari ternyata dijumpai ketidaksesuaian dengan kenyataan, saya sanggup menerima risikonya.



Demikian biodata ini saya buat dengan sebenarnya untuk memenuhi salah satu persyaratan dalam pengajuan Etik penelitian pada Manusia untuk Komisi Etik Universitas Hasanuddin Makassar.

Makassar, 4 September 2023



dr. Reskiana Syahrir





Optimized using
trial version
www.balesio.com
